Our results also revealed that ADSC treatment effectively inhibited the increased CML and RAGE levels, suggesting an anti-glycation activity of ADSC (Fig. 5A & B, CML and RAGE panel). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.